JP2020511991A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511991A5
JP2020511991A5 JP2019553350A JP2019553350A JP2020511991A5 JP 2020511991 A5 JP2020511991 A5 JP 2020511991A5 JP 2019553350 A JP2019553350 A JP 2019553350A JP 2019553350 A JP2019553350 A JP 2019553350A JP 2020511991 A5 JP2020511991 A5 JP 2020511991A5
Authority
JP
Japan
Prior art keywords
lentiviral vector
item
vector according
cell
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019553350A
Other languages
English (en)
Japanese (ja)
Other versions
JP7228523B2 (ja
JP2020511991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025165 external-priority patent/WO2018183692A1/en
Publication of JP2020511991A publication Critical patent/JP2020511991A/ja
Publication of JP2020511991A5 publication Critical patent/JP2020511991A5/ja
Priority to JP2023005869A priority Critical patent/JP2023033551A/ja
Application granted granted Critical
Publication of JP7228523B2 publication Critical patent/JP7228523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019553350A 2017-03-29 2018-03-29 ヘモグロビン異常症を治療するためのベクターおよび組成物 Active JP7228523B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023005869A JP2023033551A (ja) 2017-03-29 2023-01-18 ヘモグロビン異常症を治療するためのベクターおよび組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762478375P 2017-03-29 2017-03-29
US62/478,375 2017-03-29
US201762489149P 2017-04-24 2017-04-24
US62/489,149 2017-04-24
PCT/US2018/025165 WO2018183692A1 (en) 2017-03-29 2018-03-29 Vectors and compositions for treating hemoglobinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023005869A Division JP2023033551A (ja) 2017-03-29 2023-01-18 ヘモグロビン異常症を治療するためのベクターおよび組成物

Publications (3)

Publication Number Publication Date
JP2020511991A JP2020511991A (ja) 2020-04-23
JP2020511991A5 true JP2020511991A5 (cg-RX-API-DMAC7.html) 2021-04-30
JP7228523B2 JP7228523B2 (ja) 2023-02-24

Family

ID=63677097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553350A Active JP7228523B2 (ja) 2017-03-29 2018-03-29 ヘモグロビン異常症を治療するためのベクターおよび組成物
JP2023005869A Withdrawn JP2023033551A (ja) 2017-03-29 2023-01-18 ヘモグロビン異常症を治療するためのベクターおよび組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023005869A Withdrawn JP2023033551A (ja) 2017-03-29 2023-01-18 ヘモグロビン異常症を治療するためのベクターおよび組成物

Country Status (10)

Country Link
US (1) US12703864B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600448A4 (cg-RX-API-DMAC7.html)
JP (2) JP7228523B2 (cg-RX-API-DMAC7.html)
CN (1) CN110582305A (cg-RX-API-DMAC7.html)
AU (1) AU2018243293A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020322A2 (cg-RX-API-DMAC7.html)
CA (1) CA3057862A1 (cg-RX-API-DMAC7.html)
IL (1) IL269551A (cg-RX-API-DMAC7.html)
SG (1) SG11201908844YA (cg-RX-API-DMAC7.html)
WO (1) WO2018183692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
SG11201908844YA (en) * 2017-03-29 2019-10-30 Bluebird Bio Inc Vectors and compositions for treating hemoglobinopathies
EP3942046A1 (en) * 2019-03-22 2022-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b- hemoglobinopathies
JP7853100B2 (ja) * 2019-06-05 2026-04-28 オーチャード セラピューティクス(ヨーロッパ)リミテッド 真核細胞を修飾するための組成物及び方法
JP7803014B2 (ja) * 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
CN117384967A (zh) * 2020-04-24 2024-01-12 康霖生物科技(杭州)有限公司 一种核酸构建体
EP4222271A4 (en) * 2020-11-23 2025-07-30 Intas Pharmaceuticals Ltd LENTIVIRUS VECTOR GENE THERAPY-BASED DELIVERY FOR THE TREATMENT OF HEMOGLOBINOPATHIES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US20080051431A1 (en) 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
GB0713183D0 (en) 2007-07-06 2007-08-15 King S College London Method
US20110294144A1 (en) 2008-02-12 2011-12-01 Kenichi Noguchi Screening method
ES2738980T3 (es) 2008-09-15 2020-01-28 Childrens Medical Ct Corp Modulación de BCL11A para el tratamiento de hemoglobinopatías
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2012073047A2 (en) 2010-12-03 2012-06-07 Genome Research Limited Compositions and methods
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
DK2717922T3 (en) 2011-06-10 2019-01-07 Bluebird Bio Inc GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
ES2708948T3 (es) 2012-11-27 2019-04-12 Childrens Medical Ct Corp Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal
US10106816B2 (en) * 2012-12-14 2018-10-23 Case Western Reserve University Genomic RNA packaging enhancer element
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
ES2721936T3 (es) 2013-11-13 2019-08-06 Childrens Medical Center Regulación de la expresión genética mediada por las nucleasas
US10982339B2 (en) 2014-04-25 2021-04-20 C2Cnt Llc Process for the production of ammonia from air and water
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
CN106794260B (zh) 2014-04-25 2021-02-23 儿童医疗中心有限公司 治疗血红蛋白病的组合物和方法
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
BR112017004349A2 (pt) 2014-09-04 2017-12-05 Memorial Sloan Kettering Cancer Center terapia com gene de globina para o tratamento de hemoglobinopatias
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
KR102598130B1 (ko) 2015-03-31 2023-11-02 글리코토페 게엠베하 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
EP4014996A1 (en) 2015-08-31 2022-06-22 Helixmith Co., Ltd Anti-sialyl tn chimeric antigen receptors
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
US11261441B2 (en) * 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
SG11201908844YA (en) * 2017-03-29 2019-10-30 Bluebird Bio Inc Vectors and compositions for treating hemoglobinopathies

Similar Documents

Publication Publication Date Title
JP2019504635A5 (cg-RX-API-DMAC7.html)
US12234476B2 (en) VCN enhancer compositions and methods of using the same
US20220259594A1 (en) Vectors and compositions for treating hemoglobinopathies
EP2169073B1 (en) Vector for the preparation of immunotherapeutical compositions
EP2760994B2 (en) Compounds for improved viral transduction
AU2015315726B2 (en) Lentiviral vector for treating hemoglobin disorders
JP2014530012A5 (cg-RX-API-DMAC7.html)
US11976293B2 (en) Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
JP2015529466A (ja) 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
US20220073951A1 (en) Systems and methods for the treatment of hemoglobinopathies
US11326183B2 (en) VCN enhancer compositions and methods of using the same
CN1522160A (zh) 编码人珠蛋白基因的载体及其在治疗血红蛋白病中的应用
US11261441B2 (en) Vectors and compositions for treating hemoglobinopathies
US20250235480A1 (en) Vectors combining anti-sickling beta-as3-globin with anti bcel11a shrnamir to treat beta-hemoglobinopathies
WO2019213011A1 (en) Compositions and methods for hemoglobin production
EP3931338A1 (en) Augmentations to lentiviral vectors (cclc-mgata/ank-core lcr-beta-as3-fb) to increase expression
WO2023038055A1 (ja) レトロウイルスベクター製造用の核酸
Malik et al. Genetically engineered cures: gene therapy for sickle cell disease
CN120187857A (zh) 调控序列及其用途
HK1093523B (en) Lentiviral vectors for the preparation of immunotherapeutical compositions